Loading
Tumour DNA in blood can be told apart by chemical marks as well as mutations. Marks are more numerous and cheaper to read, so they could track more sub-populations for less money.
Mutation-based clone tracking needs deep whole-exome or genome sequencing of tumour and plasma. Methylation haplotypes are clone-stable, abundant, and readable with targeted enrichment at lower cost. The proposal is to define clone-specific methylation haplotypes from multi-region tumour tissue and monitor their plasma fractions as a low-cost clonal evolution assay.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares DNA methylation profiling, Tumour heterogeneity and clonal evolution, Liquid biopsy (ctDNA).
Shares GRAIL, DNA methylation profiling, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares GRAIL, DNA methylation profiling, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares GRAIL, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).